The latest price target for Astrana Health (NASDAQ:ASTH) was reported by BTIG on February 2, 2026. The analyst firm set a price target for $40.00 expecting ASTH to rise to within 12 months (a possible 61.81% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Astrana Health (NASDAQ:ASTH) was provided by BTIG, and Astrana Health maintained their buy rating.

The last upgrade for Astrana Health Inc happened on July 11, 2024 when Truist Securities raised their price target to $50. Truist Securities previously had a hold for Astrana Health Inc.

There is no last downgrade for Astrana Health.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astrana Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astrana Health was filed on February 2, 2026 so you should expect the next rating to be made available sometime around February 2, 2027.

While ratings are subjective and will change, the latest Astrana Health (ASTH) rating was a maintained with a price target of $45.00 to $40.00. The current price Astrana Health (ASTH) is trading at is $24.72, which is out of the analyst’s predicted range.